CSL Shares Rebound 30%, As Battleground Levels Form

CSL shares (ASX: CSL) closed at A$119.52 on Tuesday, marking a 2.69% gain and capping an impressive 30% rally from lows struck eight weeks ago, though the biotech giant remains down more than 30% year-to-date as it approaches resistance levels.

The strong close at the session high signals renewed buying interest in Australia’s largest healthcare company, with the CSL share price now pressing against the closely-watched A$120-A$125 resistance zone that has repeatedly capped recovery attempts in recent weeks. The rebound has pushed CSL’s market capitalisation to A$57.24 billion, edging closer to Fortescue Metals Group’s A$57.58 billion valuation and positioning the company to reclaim a top-10 spot among ASX primary listings.

CSL Shares Fighting Back

The dramatic recovery follows a brutal sell-off earlier this year that saw CSL shares plunge below A$100 for the first time in years. The capitulation was triggered by a perfect storm of negative developments: a material cut to earnings guidance, an approximately A$5 billion impairment charge related to the Vifor acquisition and nephrology portfolio, and leadership uncertainty surrounding the transition to an interim CEO.

The impairment charge, one of the largest in recent ASX history, crystallised growing investor concerns about the returns on CSL’s 2022 acquisition of Swiss pharmaceutical company Vifor. Markets had already been questioning whether the plasma collection economics and Vifor integration justified the capital deployed, and the writedown confirmed fears that management had overpaid for the asset. The combination of reduced earnings expectations and balance sheet damage led to a rapid derating of the premium valuation CSL had commanded for years.

However, the tide appears to have turned following the company’s Interim CEO 90-Day Review and Financial Update released in May. The review outlined concrete steps to improve plasma business margins, address donor fee inflation, and sharpen operational focus across business units.

The plasma-derived therapies business, CSL’s core franchise, continues to benefit from structural demand drivers including ageing populations, higher diagnosis rates for immune deficiencies, and expanding emerging market penetration. The company’s Seqirus vaccines division has maintained momentum with its cell-culture influenza vaccine FLUCELVAX, while the broader pipeline includes next-generation platforms in mRNA and gene therapy, notably the haemophilia B treatment HEMGENIX.

From a technical perspective, the recent price action has support stepping in from oversold levels, and the intraday high close indicates strong buying appetite, and potential for a decisive break above the A$120-A$125 resistance zone.

Yet the resistance itself reflects the challenge CSL faces in fully restoring market confidence. Each attempt to push into the low-A$120s so far has met with selling pressure, likely from longer-term shareholders using rallies to exit positions or reduce exposure after the year’s losses. The stock’s 30% year-to-date decline means many holders remain underwater, creating a potential technical overhang that could cap further gains absent a clear positive catalyst.

What Lay Ahead?

The capital allocation credibility gap remains central to the bear case. The A$5 billion impairment acknowledged that management misjudged the value creation potential of the Vifor acquisition, raising questions about return on invested capital across the enlarged group.

Bulls counter that the impairment is a non-cash, backward-looking adjustment that clears the decks for future growth. They emphasise that CSL’s fundamental business model of producing essential, high-barrier-to-entry biological therapies with long-duration demand, remains intact. The diversified portfolio spanning immunology, haematology, nephrology, and vaccines provides multiple growth vectors, while the company’s global scale and R&D capabilities are unmatched among ASX-listed healthcare companies.

The path forward remains uncertain, with bulls and bears making legitimate arguments on either side. The 30% rebound from lows demonstrates that appetite exists for CSL shares at the right price, but the persistent resistance around A$120-A$125 and the 30% year-to-date loss underscore the damage to sentiment from the guidance cut and impairment.